MedTrace Logo

Assessment of Rituximab Therapeutic Response Versus Conventional Treatment

NCT05553496 · Status: UNKNOWN · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2022-09-23

No results posted yet for this study

Summary

Prospective interventional comparative study to compare the efficacy of Rituximab versus Conventional treatment in Refractory Nephrotic Syndrome including patients on triple immunosuppression protocols.

Conditions

  • Pharmacological Action

Interventions

DRUG

Rituximab

Group (1) RTX in Refractory Nephrotic syndrome patients on conventional treatment (20 patients)

DRUG

Dexamethasone

Group (2) Refractory Nephrotic Syndrome patients on Conventional therapy (20 patients)

Sponsors & Collaborators

  • Ain Shams University

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-09-25
Primary Completion
2023-04-01
Completion
2023-10-01

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05553496 on ClinicalTrials.gov